Merck: Zepatier beats Sovaldi regimen in Phase III study

Merck & Co. Inc. (NYSE:MRK) said efficacy and safety of Zepatier grazoprevir/elbasvir were superior to Sovaldi sofosbuvir plus peginterferon and ribavirin in the Phase III C-EDGE Head-to-Head study to treat HCV genotype 1 and 4 infection.

Gilead Sciences Inc. (NASDAQ:GILD) markets Sovaldi to treat HCV genotypes 1, 2, 3 and 4. Merck markets Zepatier to treat genotypes 1 and 4. ...